4219-52-7
物理化学性质
| 沸点 | 470.0±14.0 °C(Predicted) |
| 密度 | 1.574±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO: < 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension. |
| 酸度系数(pKa) | -1.90±0.20(Predicted) |
| 形态 | Solid |
| 颜色 | Light yellow to yellow |
NSC745885价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-119198 | NSC745885 NSC745885 | 4219-52-7 | 5mg | 2000元 |
| 2024/11/08 | HY-119198 | NSC745885 NSC745885 | 4219-52-7 | 10mg | 3200元 |
| 2024/08/19 | HY-119198 | NSC745885 NSC745885 | 4219-52-7 | 50mg | 9800元 |
常见问题列表
|
EZH2
|
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC 50 of NSC745885 is 0.85 μM after 72 hours’ treatment.NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.
Cell Viability Assay
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM |
| Incubation Time: | 24, 48, or 72 hours |
| Result: | Decreases SAS cells growth as a time and dose-dependent manner. |
Apoptosis Analysis
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM |
| Incubation Time: | 24 hours |
| Result: | Decreases SAS cells growth as a time and dose-dependent manner. |
Western Blot Analysis
| Cell Line: | SAS cells is obtained from a poorly differentiated human squamous cell carcinoma |
| Concentration: | 0.5 μM, 1 μM, 1.5 μM, 2 μM |
| Incubation Time: | 24 or 48 hours |
| Result: | Increased cleaved caspase-3 expression and decreased XIAP expression. |
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.
| Animal Model: | Eight-week-old NOD/SCID (NOD.CB17 Prkdc scid /J) mice |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection; 2 mg/kg; once daily; 10 days |
| Result: | Inhibited engrafted tumors growth in vivo. |